erlotinib hydrochloride has been researched along with Papulosquamous Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Del Giudice, P; Delord, JP; Hubiche, T; Roché, H; Sibaud, V; Tournier, E | 1 |
| Ashida, A; Koizumi, T; Ogawa, E; Okuyama, R; Uhara, H | 1 |
2 other study(ies) available for erlotinib hydrochloride and Papulosquamous Disorders
| Article | Year |
|---|---|
Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity.
Topics: Adult; Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pruritus; Quinazolines; Skin Diseases, Papulosquamous; Staphylococcal Infections; Staphylococcus aureus | 2016 |
Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash.
Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; NF-kappa B; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Sebaceous Glands; Signal Transduction; Skin Diseases, Papulosquamous; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |